Fidelis Capital Partners LLC Has $5.04 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Fidelis Capital Partners LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 8.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,609 shares of the company's stock after buying an additional 2,636 shares during the quarter. Fidelis Capital Partners LLC's holdings in Johnson & Johnson were worth $5,041,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC grew its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC grew its position in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after purchasing an additional 1,022 shares during the last quarter. Proficio Capital Partners LLC grew its position in shares of Johnson & Johnson by 22.0% in the fourth quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock valued at $2,885,000 after purchasing an additional 3,594 shares during the last quarter. Integras Partners LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $2,265,000. Finally, LBP AM SA grew its position in shares of Johnson & Johnson by 8.5% in the fourth quarter. LBP AM SA now owns 396,783 shares of the company's stock valued at $57,383,000 after purchasing an additional 30,970 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on JNJ shares. Raymond James Financial cut their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Barclays cut their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Bank of America cut their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Stock Down 0.5%

Shares of JNJ opened at $156.87 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock has a market capitalization of $377.44 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.15 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a fifty day moving average of $153.75 and a 200-day moving average of $154.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.